introduction {#mdu498_s1}
============

Breast cancer is widely recognized as a heterogeneous disease in the sense of both primary tumor metastatic capacity and time to metastatic spread of disease. Treatment with endocrine therapy is a major cornerstone in the management of breast cancer and has considerably improved patient survival. However, despite considerable progress, one of five women with early-stage breast cancer will later develop distant metastatic disease \[[@MDU498C1]\].

We and others have recently shown that tumor characteristics are altered throughout tumor progression \[[@MDU498C2]--[@MDU498C4]\], which significantly influences patient survival \[[@MDU498C2], [@MDU498C5]\]. These findings emphasize the need for re-examination of tumor characteristics at relapse to improve patient management and have led to recommendations from the ABC1, ASCO, ESMO, and Swedish Breast Cancer group (SweBCG), among others, regarding the re-evaluation of metastatic lesions for expression of estrogen (ER), progesterone (PR), and human epidermal receptor 2 (HER2) \[[@MDU498C6]--[@MDU498C8]\].

Here, we aimed to enhance our understanding of the biology of breast cancer metastases in relation to post-relapse survival and to assess tumor characteristics with previously demonstrated prognostic significance in the primary tumor setting to understand their importance in metastatic disease. Our goal in doing so is to provide biologically relevant information that will help to guide individualized patient management. We analyzed tumor characteristics from one or more metastases of 111 breast cancer patients enrolled in the Swedish multicenter prospective and randomized TEX \[Taxol^®^ (paclitaxel): Bristol-Myers Squibb AB, Sweden; Farmorubicin® (epirubicin): Pfizer AB, Sweden; Xeloda® (capecitabine): Roche AB, Sweden\] trial.

patients and methods {#mdu498_s2}
====================

The Swedish multicenter and randomized trial TEX \[[@MDU498C9]\], ClinicalTrials.gov identifier NCT01433614 (<http://www.clinicaltrials.gov/ct2/show/NCT01433614>), enrolled 287 patients with a morphologically confirmed locoregional or distant breast cancer relapse from December 2002 until June 2007. Previous endocrine treatment of advanced disease in patients with hormone receptor-positive breast cancer was allowed. In addition, previous treatment with an anthracycline, a taxane, or 5-FU was allowed if the last course of chemotherapy was given at least 1 year before TEX study entry. Patients were randomly assigned to first-line chemotherapy with a combination of epirubicin and paclitaxel alone or in combination with capecitabine. Detailed clinical information and complete follow-up were available for all included patients.

Patients with metastatic lesions accessible for either a fine-needle aspiration (FNA) or a core biopsy were asked to give a sample, but sampling was optional. We defined the site of relapse as the site where the metastatic biopsy was taken. The most common biopsy sites were lymph nodes (36.7%), liver (22.5%), skin (18.3%), and breast (15.8%). In total, tumor tissue was available from 149 of 287 patients.

The translational aspect of the trial included 120 relapse biopsies (116 FNA biopsies and 4 core biopsies) from 111 patients yielding sufficient tumor RNA for gene expression profiling. The clinical and pathological patient characteristics of the translational TEX trial were representative of the original TEX trial.

Details of the HRSTA-2.0 custom human Affymetrix array GPL10379 are available at NCBI GEO depository as GPL10379 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL10379>). Briefly, this whole-genome array contains 52 378 individual probe sets, with each probe set containing 4--20 individual probes. The gene expression microarray data have been deposited into the Gene Expression Omnibus under the accession number of GSE56493.

This study was approved by the Ethics committee at Karolinska Institutet and the other participating centers. All patients have given written informed consent.

statistical methods {#mdu498_s2a}
-------------------

### preprocessing and normalization {#mdu498_s2a1}

The relapse tumor gene expression analyses were performed in the open-source software R using the aroma.affymetrix package \[[@MDU498C10]\]. Each gene expression array was individually background corrected and normalized using robust multichip averaging; no arrays were identified as having poor quality. The quality of the arrays was assessed utilizing Normalized Unscaled Standard Error plots and Relative Log Expression plots.

### survival analysis {#mdu498_s2a2}

Patient follow-up started at the date of the TEX study enrollment and ended at the date of death, or at the end of study follow-up, 1 July 2013. We carried out Kaplan--Meier and multivariate proportional hazard (Cox) analyses adjusting for calendar year and age at diagnosis in addition to the TEX clinical study treatment arms. We did not adjust for additional tumor characteristics due to sample size. The proportional hazard assumption for the main exposure variables was assessed including a time-dependent covariate in the survival model. No significant deviation was noted.

Breast cancer-specific survival was used as the end point. Post-relapse patient survival was defined as short-term (up to 1.5 years post-relapse survival) and long-term survival (up to 5 years or more). The short-term survival cutoff (1.5 years post-relapse survival) was defined retrospectively by applying a model of two normal distributions, in order to capture the visually apparent survival distribution, using the mixtools package in R \[[@MDU498C11]\]. A full description of this is provided in [supplementary Materials and methods, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1).

### intrinsic subtype {#mdu498_s2a3}

We assessed the intrinsic subtypes (PAM50) for each relapse using the TEX metastasis gene expression arrays as previously described; full details are provided in [supplementary Materials and methods, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1) \[[@MDU498C12]\].

### gene modules {#mdu498_s2a4}

To characterize the tumor biology of the breast cancer relapses, we applied the set of 7 gene expression process modules and 10 pathway modules as previously described \[[@MDU498C13], [@MDU498C14]\]. Each module is comprised of genes both positively and negatively associated with the gene of interest (e.g. *ESR1*) and the module as a whole is representative of a biological process/pathway. We computed the module score for every gene module in the relapses and divided the resulting continuous variables into tertiles as described in the original publications. The tertiles were grouped so that the most clinically aggressive tertile was compared with the remaining two.

Hierarchical clustering was used to indicate relapse sample similarity with respect to post-relapse survival (short- or long-term, see definition above) and relapse site.

### single probe association {#mdu498_s2a5}

Differential gene expression according to short- or long-term post-relapse patient survival (as defined above) was analyzed using the open-source R package OCplus 1.22.0 \[[@MDU498C15]\]. For additional information, see [supplementary Methods, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1).

All data preparation and analysis were done using SAS version 9.3 and R version 2.15.2.

results {#mdu498_s3}
=======

The clinico-pathological characteristics of the 111 patients included in the translational TEX trial are summarized in Table [1](#MDU498TB1){ref-type="table"}. The majority of patients were diagnosed with primary breast cancer from 1995 onwards and as expected from a clinically aggressive cohort, there were high numbers of ER negative (37.5%), PR negative (51.5%), grade 3 (52.4%), and stage IV (14.8%) tumors at primary tumor diagnosis. Metastatic sites were distributed as follows: breast (15.8%), liver (22.5%), lung/pleura (1.7%), lymph node (36.7%), skeleton (4.2%), skin (18.3%), and other 0.8%.Table 1.Patient and tumor characteristics of the patients included in the translational TEX trialPatientsNumberPercentAge at primary tumor diagnosis, years \<452724.3 45--554540.5 \>553935.2Calendar period of primary tumor diagnosis 1985--198943.6 1990--199465.4 1995--19992623.4 2000--20077567.6Primary tumor characteristics Estrogen receptor status  Positive6562.5  Negative3937.5  Unknown7-- Progesterone receptor status  Positive4748.5  Negative5051.5  Unknown14-- Elston--Ellis tumor grade  144.9  23542.7  34352.4  Unknown29-- T stage at diagnosis  T13633.3  T24339.8  T31312.1  T41614.8  Unknown3-- N stage at diagnosis  N03230.2  N16561.3  N287.5  N311.0  Unknown5-- M stage at diagnosis  M08576.6  M12623.4Adjuvant therapy Endocrine therapy  Yes4742.3  No6457.7 Radiotherapy  Yes6457.7  No4742.3 Chemotherapy  Yes4843.2  No6356.8

gene expression modules of biological processes reflect the aggressive nature of breast cancer metastases {#mdu498_s3a}
---------------------------------------------------------------------------------------------------------

To characterize the tumor biology of breast cancer metastases, we assessed a set of seven biologically relevant gene expression modules in our 120 metastatic samples \[[@MDU498C13]\]. For visualization purposes, we selected those genes positively correlated with each module from our samples and carried out hierarchical clustering (Figure [1](#MDU498F1){ref-type="fig"}A and B). All gene modules (AURKA---proliferation, CASP3---apoptosis, ERBB2---HER2 signaling, ESR1---ER signaling, PLAU---tumor invasion/metastasis, STAT1---immune response, and VEGF---angiogenesis) show a varying range of expression values emphasizing the biological diversity between metastases. The aggressive nature of these tumors is also readily apparent with the majority displaying high expression of genes related to proliferation (AURKA module) and approximately half exhibiting low *ESR1*-related expression (ESR1 module). The seven patients in our cohort with multiple gene expression arrays (either several biopsies on the same metastatic site or different sites) are indicted with colored arrows and numbers (Figure [1](#MDU498F1){ref-type="fig"}A, bottom of the heatmap). The paired metastases from four of seven patients cluster immediately beside one another (numbers 1, 4, 5, and 7). Conversely, three metastatic biopsy pairs from the same patient and relapse cluster separately (numbers 2, 3, and 6), indicating gene expression pattern differences between these intrarelapse tumor biopsies. Figure 1.Hierarchical clustering of gene expression profiles of breast cancer metastases based on module genes reflecting seven biological processes (A) Positively correlated module genes were selected for visual representation of 120 breast cancer metastatic samples. Arrows indicate patients with multiple metastases. AURKA, proliferation; CASP3, apoptosis; ERBB2, HER2 signaling; ESR1, estrogen signaling; PLAU, tumor invasion/metastasis; STAT1, immune response; VEGF, angiogenesis. (B) Zoom-in of CASP3 and VEGF modules.

low ESR1 and CASP3 gene module scores are associated with poor post-relapse survival {#mdu498_s3b}
------------------------------------------------------------------------------------

Long- and short-term Kaplan--Meier survival curves for the ESR1 and CASP3 gene modules are shown in Figure [2](#MDU498F2){ref-type="fig"} A and B, (left panels, and for the remaining modules in [supplementary Figures S1 and S2, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1). Patients with a low CASP3 module score demonstrated poor long-term survival relative to those with an intermediate/high score (Figure [2](#MDU498F2){ref-type="fig"}B, left panel, *P* = 0.0010). In addition, low ESR1 and CASP3 module scores were associated with poor short-term breast cancer-specific survival (Figure [2](#MDU498F2){ref-type="fig"}A and B, right panels, *P* = 0.0078 and *P* = 0.045, respectively). Furthermore, using a multivariate proportional hazard (Cox) model adjusting for age at diagnosis, diagnosis date, and TEX clinical study treatment received, a more than twofold increased risk for death from breast cancer (short-term survival) was found in patients whose tumors had low CASP3 and ESR1 module scores \[hazard ratio (HR) 2.2; 95% confidence interval (CI) 1.1--4.1 and 2.2; 95% CI 1.2--4.2, respectively\], see Table [2](#MDU498TB2){ref-type="table"} (significant risk estimates in bold) and [supplementary Figures S1 and S2, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1).Table 2.Multivariate analysis of gene modules and subtypes in relation to patient post-relapse survivalLong-term breast cancer-specific survivalShort-term breast cancer-specific survival^^b^^HR95% CI*P* valueHR95% CI*P* valueModule^a^ (*n* = 111) ESR1 low^c^1.30.8--2.10.27**2.21.2--4.20.01** ERBB2 high^^d^^0.80.5--1.40.460.80.4--1.50.47 AURKA high^^d^^1.20.8--2.00.381.10.5--2.10.89 PLAU high^^d^^1.20.7--1.90.521.40.8--2.70.25 VEGF low^c^1.00.6--1.60.951.50.8--2.80.21 STAT1 low^c^1.00.6--1.60.990.80.4--1.60.58 CASP3 low^c^**2.71.7--4.5\<0.0012.21.1--4.10.02**PAM50^a^ (*n* = 105) Luminal A (Ref.)1.0----1.0---- Luminal B2.30.8--6.90.122.40.3--19.50.42 HER2-enriched**4.41.5--12.80.017.61.0--58.20.05** Basal-like**3.71.3--10.90.027.21.0--54.60.06**[^1][^2][^3][^4][^5] Figure 2.Long- and short-term breast cancer-specific post-relapse survival in relation to gene module groups (A) ESR1 module tertiles long-term (5 years) and short-term (1.5 years) breast cancer-specific survival, respectively. (B) CASP3 module tertiles long- and short-term post-relapse survival, respectively. A *P* value is based on the log-ranked test, and numbers at risk are shown underneath each graph.

gene module scores representative of the AKT-MTOR, RAS, and BETA-C signaling pathways are associated with poor post-relapse survival {#mdu498_s3c}
------------------------------------------------------------------------------------------------------------------------------------

To further characterize the biology of our metastatic samples, we extended our gene module analysis to include a set of 10 previously described biologically relevant signaling pathways (Ras, MAPK, PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3, and β-catenin) \[[@MDU498C14]\]. In summary, high AKT-MTOR (*P* log rank = 0.03, HR 1.7; 95% CI 1.1--2.7), RAS (*P* log rank = 0.03, HR 1.8, 95% CI 1.1--2.9), and BETA-C (P log rank = 0.03, HR 1.7, 95% CI 1.1--2.7) module scores were significantly associated with long-term poor post-relapse survival ([supplementary Figures S3--S6, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1)).

breast cancer molecular subtypes of metastases provide information of post-relapse survival {#mdu498_s3d}
-------------------------------------------------------------------------------------------

Overall, 25% of the metastases were basal-like (*n* = 30), 32% HER2-enriched (*n* = 38), 10% luminal A (*n* = 12), 28% luminal B (*n* = 34), and 5% normal-like. These subtypes were significantly associated with survival in the Kaplan--Meier analysis (*P* = 0.008, Figure [3](#MDU498F3){ref-type="fig"}A) with the shortest survival seen in the basal-like and HER2-enriched subgroups. Furthermore, using a multivariate proportional hazard (Cox) model adjusting for age at diagnosis, diagnosis date, and TEX clinical study treatment received, a more than threefold increased risk for death from breast cancer was found in patients whose tumors were basal-like and HER2-enriched (HR 3.7; 95% CI 1.3--10.9 and 4.4; 95% CI 1.5--12.8, respectively), see Table [2](#MDU498TB2){ref-type="table"}. Figure 3.The PAM50 intrinsic subtypes in relation to long- and short-term post-relapse breast cancer-specific survival. (A) The PAM50 intrinsic subtypes in relation to long-term (5 years) breast cancer-specific survival. (B) The PAM50 intrinsic subtypes in relation to short-term (1.5 years) breast cancer-specific survival. A *P* value is based on log-ranked test, and numbers at risk are shown underneath each graph.

basal-like, cell cycle, and mesenchymal-related genes are upregulated in patients with short-term post-relapse survival {#mdu498_s3e}
-----------------------------------------------------------------------------------------------------------------------

Finally, in an effort to understand genetic differences between tumors of patients with short-term versus long-term survival, we carried out differential gene expression analysis to identify a poor metastasis survival signature. The poor metastasis survival signature included 136 unique genes differentially expressed between patients with short-term compared with long-term post-relapse survival. The expression of the included genes is presented in [supplementary Figure S7, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1) and the full gene list is also provided in [supplementary Table S1, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1). Strikingly, patients with short-term survival ([supplementary Figure S7, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1), red in the horizontal sidebar) displayed increased expression of the epithelial to mesenchymal marker *SNAI1*, the cell cycle markers *CCNE1*, *CDC25B*, and the basal/triple-negative-associated gene *CAV2*. Moreover, the same patients showed reduced expression of the *ESR1*, *GATA3*, and *FOXA1* genes, all of which are linked to a luminal breast phenotype and ER receptor expression. A gene ontology analysis of these 136 genes is also provided in [supplementary Table S2, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1). These results are in line with our earlier findings, showing a worse survival outcome in patients with a low ESR1 module score and basal-like subtype.

discussion {#mdu498_s4}
==========

It is now accepted that standard breast cancer markers alter their expression throughout tumor progression \[[@MDU498C2]--[@MDU498C5]\], which significantly influences patient survival \[[@MDU498C2], [@MDU498C5]\]. As such, investigation of tumor characteristics at relapse has the potential to improve patient management and survival. However, in order to be able to further individualize patient management in the metastatic setting, we need a better understanding of the association between metastatic tumor characteristics and patient survival. If tumor aggressiveness as assessed by the prognostic markers in the primary setting can be translated to the metastatic setting, this information would be clinically relevant.

To enhance our current understanding of tumor biology in breast cancer metastases, we analyzed the TEX randomized trial that included 111 patients with available gene expression information from one or more metastatic lesions. Specifically, we assessed gene modules representative of tumor biological processes and pathways, as well as, the intrinsic subtypes \[[@MDU498C12]\], in all metastatic samples and related our findings to patient survival. Interestingly, a significant reduction in post-relapse breast cancer-specific survival was demonstrated for patients with the lowest levels of ER receptor signaling (ESR1 module) and apoptosis (CASP3). Furthermore, high AKT-MTOR, RAS, as well as BETA-C (β-catenin) signaling were significantly associated with poor post-relapse survival. Similarly, the intrinsic subtypes in the metastases provided statistically significant post-relapse survival information, with the worst survival outcome in the basal-like and HER2-enriched subtypes. Additionally, patients with poor post-relapse survival showed high metastasis expression levels of basal-like, cell cycle, and mesenchymal-related genes with concomitant low expression of luminal genes.

While little is known about the biology of breast cancer metastases themselves, the steps governing the progression from primary breast tumor to seeding of distant metastatic lesions has been a focal point of intense investigation (for review see refs. \[[@MDU498C16], [@MDU498C17]\]). These steps comprise what is typically termed 'the metastatic cascade' and consist of invasion/proliferation into the tissue surrounding the primary tumor, intravasation to blood or lymph vessels, extravasation to distal organs, and finally colonization of the distant tumor microenvironment. With regard to colonization, one of the main processes that have been hypothesized as essential to the successful development of metastatic breast tumors is cell proliferation \[[@MDU498C17]\]. Through application of the AURKA gene module, we demonstrate that the vast majority of our samples are highly proliferative; this finding is also supported by the intrinsic subtypes where the majority of tumors are luminal B, HER2-enriched, and basal-like subtypes---all of which are associated with high levels of proliferation. Of note, the luminal A subtype of tumors that are known to display lower levels of proliferation have the best post-relapse survival in our dataset \[[@MDU498C18]\]. These results may emphasize the importance of proliferation in relation to survival in metastatic tumors, at least in tumors of luminal subtype, and indicate that a routinely employed proliferative marker, such as Ki-67, could also prove informative in a clinical setting.

In conclusion, an enhanced understanding of the biology of breast cancer metastases is needed to improve both patient survival in the metastatic setting and prediction of which patients are at high risk to later develop metastatic breast cancer disease. We show that the tumor characteristics of metastases significantly influence post-relapse patient survival emphasizing that molecular investigation at relapse offers clinically relevant information, with the potential to improve patient management and survival in the relapse setting.
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[^1]: ^a^Adjusted for age at diagnosis, diagnosis date, and treatment received.

[^2]: ^b^1.5-year survival.

[^3]: ^c^Intermediate/high as reference group.

[^4]: ^d^Low/intermediate as reference group.

[^5]: HR, hazard ratio; CI, confidence interval.
